

---

## Overview

### Useful For

Monitoring response to therapy in patients with known e1/a2 *BCR/ABL1* (p190) fusion forms

### Testing Algorithm

See [BCR/ABL1 Ordering Guide for Blood and Bone Marrow](#)

### Special Instructions

- [Hematopathology Patient Information](#)
- [BCR/ABL1 Ordering Guide for Blood and Bone Marrow](#)

### Method Name

Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR)

### NY State Available

Yes

## Specimen

### Specimen Type

Varies

### Ordering Guidance

This test should not be used to screen for *BCR/ABL1* fusions at the time of diagnosis; order either BADX / *BCR/ABL1*, Qualitative, Diagnostic Assay, Varies; or BCRFX / *BCR/ABL1* Qualitative Diagnostic Assay with Reflex to *BCR/ABL1* p190 Quantitative Assay or *BCR/ABL1* p210 Quantitative Assay, Varies should be ordered for that purpose.

To monitor patients carrying *BCR/ABL1* fusion forms coding for the p210 protein, which includes most patients with chronic myeloid leukemia (CML); order BCRA B / *BCR/ABL*, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myeloid Leukemia (CML), Varies.

### Shipping Instructions

**Refrigerate specimens must arrive within 5 days (120 hours) of collection, and ambient specimens must arrive within 3 days (72 hours) of collection.** Collect and package specimen as close to shipping time as possible.

### Necessary Information

The following information is required:

1. Pertinent clinical history including if the patient has a diagnosis of chronic myeloid leukemia or other

---

BCR/ABL1-positive neoplasm

2. Date of collection
3. Specimen source (blood or bone marrow)

**Specimen Required****Submit only 1 of the following specimens:****Preferred:****Specimen Type:** Whole blood**Container/Tube:****Preferred:** Lavender top (EDTA)**Acceptable:** Yellow top (ACD)**Specimen Volume:** 10 mL**Collection Instructions:**

1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. **Do not aliquot.**
3. Label specimen as blood.

**Specimen Type:** Bone marrow**Container/Tube:****Preferred:** Lavender top (EDTA)**Acceptable:** Yellow top (ACD)**Specimen Volume:** 4 mL**Collection Instructions:**

1. Invert several times to mix bone marrow.
2. Send bone marrow specimen in original tube. **Do not aliquot.**
3. Label specimen as bone marrow.

**Forms**

1. [Hematopathology Patient Information](#) (T676)
2. If not ordering electronically, complete, print, and send a [Hematopathology/Cytogenetics Test Request](#) (T726) with the specimen.

**Specimen Minimum Volume**

Blood: 8 mL

Bone marrow: 2 mL

**Reject Due To**

Gross hemolysis	Reject
Moderately to severely clotted	Reject

**Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Varies	Refrigerated (preferred)	5 days	PURPLE OR PINK TOP/EDTA
	Ambient	72 hours	PURPLE OR PINK TOP/EDTA

**Clinical & Interpretive****Clinical Information**

Messenger RNA (mRNA) transcribed from *BCR/ABL1* (fusion of the breakpoint cluster region gene [*BCR*] at chromosome 22q11 to the Abelson gene [*ABL1*] at chromosome 9q34) is detected in all patients with chronic myeloid leukemia (CML) and a subset of patients with both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Although breakpoints in the *BCR* and *ABL1* genes may occur in a variety of locations, splicing of the primary RNA transcripts result in only 8 fusion site variants (e1/a2, e6/a2, e13/a2, e14/a2, e19/a2, and e1/a3, e13/a3, e14/a3), which incorporate the entire sequence of the exons on both sides of the fusion site. The e1/a2 and e1/a3 fusion forms produce a 190-kDa protein designated p190. This *BCR/ABL1* protein form is found in approximately 75% of patients with childhood ALL and approximately 50% of patients with adult ALL, with the majority arising from e1/a2 mRNA. The p190 is also the predominant fusion form in a small subset of patients with CML, although the vast majority of CML cases contain the p210 protein, typically from e13/a2 or e14/a2 mRNA fusions. Other fusion forms are very rare.

Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) is the most sensitive method for monitoring *BCR/ABL1* levels during treatment. This test detects mRNA coding for the most common p190 fusion form (e1/a2).

**Reference Values**

The presence or absence of the *BCR/ABL1* messenger RNA fusion form producing the p190 fusion protein is reported. If positive, the level is reported as the ratio of *BCR/ABL1* (p190) transcript to *ABL1* transcript in the form of a percentage.

**Interpretation**

An interpretive report will be provided.

**Cautions**

This test detects only the e1/a2 *BCR/ABL1* (p190) fusion form. Other fusion forms are not detected by this assay, including those containing the *BCR* e13 and e14 exons, which code for the p210 protein commonly found in chronic myeloid leukemia (CML), and the rare e1/a3 (p190) fusion form.

The precision of this assay at very low *BCR/ABL1* levels is less reliable, such that inter-run variation can be more variable. If the results are being used to make major therapeutic decisions, significant changes during monitoring should be verified with a subsequent specimen.

Results of this assay cannot be directly compared with results generated from other polymerase chain reaction (PCR) assays, including identical assays performed in other laboratories. Monitoring should be performed using the same

---

method and laboratory for each subsequent specimen.

The results of this assay cannot be directly compared with *BCR/ABL1* results obtained using fluorescence in situ hybridization (FISH) technology. FISH measures DNA alleles and this PCR-based assay measures messenger RNA (mRNA) transcripts. Because a single DNA allele can produce many mRNA transcripts, the values are not directly comparable.

Blood is the specimen of choice for monitoring. While most patients show similar *BCR/ABL1* levels in blood and bone marrow drawn at the same time, some patients have a consistent difference in the levels in blood and bone marrow such that altering specimen types during monitoring can lead to confusion.

Assay precision does not appear to be significantly affected by specimen transport or moderate delays in processing. However, in specimen with very low levels of *BCR/ABL1*, these conditions may cause sufficient RNA degradation to produce false-negative results. Thus, specimens should be shipped as quickly as possible. Ambient specimens over 3 days old and refrigerate specimens over 5 days old at the time of receipt are unacceptable.

### Clinical Reference

1. Hughes TP, Kaeda J, Branford S, et al: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. *N Engl J Med.* 2003;349:1423-1432
2. Radich JP, Gooley T, Bryant E, et al: The significance of *BCR/ABL* molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. *Blood.* 2001;98:1701-1707
3. Olavarria E, Kanfer E, Szydlo R, et al: Early detection of *BCR-ABL* transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplant for chronic myeloid leukemia. *Blood.* 2001;97:1560-1565
4. [Tefferi A: The classic myeloproliferative neoplasms: Chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, and primary myelofibrosis. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, eds. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill; 2019, Accessed March 16, 2022. Available at <https://ommbid.mhmedical.com/content.aspx?sectionid=225078035&bookid=2709>](https://ommbid.mhmedical.com/content.aspx?sectionid=225078035&bookid=2709)

### Performance

#### Method Description

Total RNA is extracted and reverse transcribed to complementary DNA. Quantitative real time polymerase chain reaction is performed and p190/*ABL* quantitative levels are determined using Taqman-type probe technology. The data is analyzed for relative quantification with calibrator normalization and efficiency correction. The reference gene, *ABL1*, is used to control for RNA degradation in the sample and the calibrator is used to control for inter-run variations. A normalized ratio of *BCR/ABL1* (p190) mRNA:*ABL1* mRNA is obtained and reported in the form of a percentage.(Unpublished Mayo method)

#### PDF Report

Supplemental

**Day(s) Performed**

Monday through Saturday

**Report Available**

4 to 8 days

**Specimen Retention Time**

Blood/Bone marrow; 2 weeks: Extracted RNA 3 months

**Performing Laboratory Location**

Rochester

**Fees & Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

81207

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
BA190	BCR/ABL1, p190, Quant, Monitor	In Process

Result ID	Test Result Name	Result LOINC® Value
MP002	Specimen Type	31208-2
19765	Interpretation	69047-9
39470	BCR/ABL1 p190 Result	No LOINC Needed